During 2013 to 2016, more than two million people in the United States had current hepatitis C virus infection.
Hepatitis C virus-negative recipients of HCV-infected kidneys experience HCV cure and good quality of life.
The Canadian Medical Association provided an updated evidence-based recommendations for the treatment of patients with chronic hepatitis C virus.
Alcohol use disorder in patients with HCV infection is associated with increased symptoms of depression and anxiety compared with patients with HCV and no history of alcohol abuse.
Universal screening is the most effective strategy for hepatitis C virus in France.
For patients with HCV infection with end-stage renal disease, transplant of an HCV-infected kidney followed by treatment is more cost-effective than transplant of an HCV-uninfected kidney.
Project ECHO at Los Angeles Christian Health Center contributes to improved care of HCV in underserved populations.
For older patients with hepatitis C virus, direct-acting antiviral therapy is effective.
Real-world data have demonstrated no rise in the development of incident liver cirrhosis among patients with psoriasis and either CHB or CHC who have received long-term MTX therapy.
Post-transplant hepatitis C treatment increases access to transplant and reduces waitlist time among hepatitis C-positive patients awaiting kidney transplantation.
The Respectful & Equitable Access to Comprehensive Healthcare program obtained 93% of prior authorization approvals for hepatitis C medications.
The guidelines were developed by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America.
A proposed novel Medicaid purchasing strategy is anticipated to increase access to medications that can eradicate hepatitis C virus infection without increasing costs at the state and federal levels.
The discontinuation is voluntary and is not related to product quality, safety or efficacy.
Low screening rate seen at same time as increase in hepatitis C virus prevalence among pregnant women.
Sofosbuvir-based treatment appears to guarantee renal safety for patients with chronic hepatitis C virus over one year of follow-up.
Methadone Maintenance Therapy Associated With Greater Access to Physician Care in HCV-Positive Drug UsersMay 10, 2018
The investigators suggest that enrollment in a methadone maintenance therapy program may be helpful in providing access to HCV care in people who inject drugs.
A 72-year-old Japanese woman with a 40-year history of lupus nephritis presented with leg edema that had lasted for several weeks.
Study results support the indication of glecaprevir/pibrentasvir as the first 8-week pangenotypic treatment option for HCV/HIV-1 coinfected patients without cirrhosis.
Katie Burk, MPH, presented measures undertaken by the city of San Francisco to provide integrated responses to the concurrent HIV/HCV and opioid public health epidemics.
Future research should develop interventions to increase HCV screening with special focus on groups demonstrating significantly lower screening rates, such as Hispanics and women.
Alcohol dependence has deleterious effects on frontal cortical volumes that are compounded by hepatitis C virus infection and drug dependence.
HCV eradication by DAA improves carotid atherosclerosis in patients with advanced fibrosis and compensated cirrhosis.
A case of remission of psoriasis after treatment of chronic hepatitis C virus has been described.
Reduced DAA delays and denials for patients with HCV reduced with provider-pharmacy collaboration.
State medical surveillance data suggest that the risk for mother-to-infant vertical transmission of hepatitis C virus is increasing.
Experts discuss the management of drug-drug interactions in patients receiving treatment for HIV and HCV coinfection.
Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin demonstrated high rates of adherence and SVR in different HCV patient subgroups, including patients with advanced fibrosis combined with chronic comorbidities.
Investigators evaluated whether unfavorable outcomes were prevented once sustained virologic response was achieved in older adults with HCV.
Safety and efficacy of sofosbuvir plus grazoprevir/elbasvir plus ribavirin was evaluated in individuals who did not achieve sustained virological response on NS5A or NS3-based therapy and RAS failure.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Predicative Factors for Relapse in Adult Bacterial Osteomyelitis
- Zika Vaccine Cost-Effective for Young Adults and Childbearing-Age Women
- Cefiderocol for the Treatment of Complicated Gram-Negative UTIs
- Stethoscope Cleaning Standards May Not Eliminate Bacterial Contamination
- Higher Viral Control in Women With HIV in Serodiscordant Relationships
- Antibiotic Use in Neonatal Settings in Need of Improvement
- Shorter Antibiotic Course Noninferior for Gram-Negative Bacteremia
- Rapid Antimicrobial Susceptibility Testing on Urine Directly Accelerates Results
- Antibiotics May Be Beneficial in Children With Prolonged Wet Cough
- Emergency Department Overcrowding Associated With Delayed Antibiotics in Patients With Sepsis
- Bacteria Bystanders Play Important Role in Antibiotic Resistance Development
- Many New Cancer Patients Unaware of Their Hepatitis Status
- Worse Outcomes in Community-Acquired Pneumonia Linked to Higher FGF21 Levels
- Bacterial Pneumonia-Complicating Influenza: Risks, Morbidity, and Mortality
- Bexsero Vaccine Has Potential for Cross-Protection Against Gonorrhea